Fusion Antibodies (LSE:FAB) Shares Outstanding (Basic Average): 113.21 Mil (As of Sep. 2025)


LSE:FAB Fusion Antibodies PLC LSE:FAB
33 GF Score
Price £0.12
GF Value £0.04
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is Fusion Antibodies Shares Outstanding (Basic Average)?

Fusion Antibodies LSE:FAB 33 Shares Outstanding (Basic Average) is 113.21 Mil as of Sep. 2025. GuruFocus rates LSE:FAB with a GF Score™ of 33/100 and a GF Value™ of £0.04 (Significantly Overvalued). The stock has 4 warning signs investors should review.

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. Fusion Antibodies's average basic shares outstanding for the quarter that ended in Sep. 2025 was 113.21 Mil.


Fusion Antibodies  (LSE:FAB) Shares Outstanding (Basic Average) Explanation

A company may buy back shares or issue shares in any fiscal period. If a company buys back shares, we should observe that the total number of shares decline. If the company issues new shares, the number of shares outstanding increases.


Be Aware

Usually the presence of treasury shares and a history of buyback are good indicators that company has competitive advantage. But studies have shown that companies usually buy back at wrong time. Buying back shares below its intrinsic value increases value for remaining shareholders. Buying back overvalued shares destroys value for existing shareholders.


Fusion Antibodies Shares Outstanding (Basic Average) Related Terms


Fusion Antibodies Shares Outstanding (Basic Average) Historical Data

* Premium members only.

The historical data trend for Fusion Antibodies's Shares Outstanding (Basic Average) can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Fusion Antibodies Shares Outstanding (Basic Average) Chart

Fusion Antibodies Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Shares Outstanding (Basic Average)
Get a 7-Day Free Trial Premium Member Only Premium Member Only 25.46 25.95 26.02 55.56 95.88

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Mar25 Sep25
Shares Outstanding (Basic Average) Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 46.50 64.62 95.37 96.39 113.21
LSE:FAB
33GF Score
Fusion Antibodies PLC LSE:FAB
Shares Outstanding (Basic Average) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Fusion Antibodies Shares Outstanding (Basic Average) Calculation

Shares outstanding are shares that have been authorized, issued, and purchased by investors and are held by them. They have voting rights and represent ownership in the corporation by the person that holds the shares. They should be distinguished from treasury shares, which are shares held by the corporation itself, having no exercisable rights.

Shares outstanding can be calculated as either basic or fully diluted. The fully diluted shares outstanding count includes diluting securities, such as options, warrants or convertibles.

Please note: GuruFocus named Shares Outstanding (EOP) is the shares for that exact time point. It is usually used to calculate balance sheet related items, such as Book Value per Share, etc. While Shares Outstanding (Diluted Average) and Shares Outstanding (Basic Average) are the weighted average shares over a period of time (a year, a quarter, or so). They are usually used to calculate income statement or cashflow statement related items, such as Earnings per Share (Diluted), etc.

What does a Shares Outstanding (Basic Average) of 113.21 Mil mean?
Fusion Antibodies (LSE:FAB) has a Shares Outstanding (Basic Average) of 113.21 Mil as of Sep. 2025. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Fusion Antibodies and its competitors.
Is Fusion Antibodies' Shares Outstanding (Basic Average) too high?
Fusion Antibodies' current Shares Outstanding (Basic Average) is 113.21 Mil. Overall, Fusion Antibodies has a GF Score™ of 33/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Fusion Antibodies' Shares Outstanding (Basic Average) compare to VRTX and REGN?
Fusion Antibodies' Shares Outstanding (Basic Average) of 113.21 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Shares Outstanding (Basic Average) for a Biotechnology company?
A good Shares Outstanding (Basic Average) depends on the Biotechnology industry context. However, Shares Outstanding (Basic Average) should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Shares Outstanding (Basic Average) mean?
A high Shares Outstanding (Basic Average) can signal that a stock is expensive relative to its fundamentals. The average shares outstanding over two periods not accounting for dilutive securities like convertible bonds. View historical data on Fusion Antibodies and its competitors. Fusion Antibodies's current Shares Outstanding (Basic Average) is 113.21 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Fusion Antibodies stock overvalued right now?
Based on GuruFocus' analysis, Fusion Antibodies (LSE:FAB) is currently considered Significantly Overvalued. The stock's GF Value™ is £0.04, compared to a current price of £0.12 — trading 187.5% above its estimated fair value. The current Shares Outstanding (Basic Average) is 113.21 Mil. Fusion Antibodies' overall GF Score™ is 33/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Shares Outstanding (Basic Average) calculated?
Shares Outstanding (Basic Average) is calculated from a company's financial statements. For Fusion Antibodies (LSE:FAB), the current Shares Outstanding (Basic Average) is 113.21 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Fusion Antibodies (LSE:FAB) Overvalued in 2026?

Based on GuruFocus' analysis, Fusion Antibodies stock appears to be overvalued. The current stock price of £0.12 is trading 187.5% above its estimated GF Value™ of £0.04. GuruFocus considers Fusion Antibodies to be Significantly Overvalued.

Key valuation signals for LSE:FAB:

  • Shares Outstanding (Basic Average): 113.21 Mil
  • GF Value™: £0.04 vs. price of £0.12 (187.5% above fair value)
  • GF Score™: 33/100 with 4 warning signs

No single metric tells the full story. See the LSE:FAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Fusion Antibodies Business Description

Address 1 Springbank Road, Springbank Industrial Estate, Dunmurry, Northern Ireland, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC is a Contract Research Organisation (CRO) providing antibody identification, engineering, and expression services for the discovery and development of antibodies for human and veterinary therapeutics, as well as for diagnostics. Its customers are pharmaceutical, biotech, veterinary, diagnostic, and life science research companies. The company's three core service areas include: Discovery (identification, screening, and sequencing of novel antibodies); Engineering (optimising the performance of antibodies); and Supply (production and purification of antibodies for further development). Geographically company generates the majority of its revenue from North America and the Rest of the World, followed by the United Kingdom and the Rest of Europe.
33GF Score

Get the complete analysis for LSE:FAB

Shares Outstanding (Basic Average) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

£0.12
Price
£0.04
GF Value